Article

FDA approves IOL for cataracts and presbyopia

Alcon Inc. has received FDA approval for a lens designed for implantation during cataract surgery in patients with presbyopia (AcrySof IQ ReSTOR +3.0 D).

Huenenberg, Switzerland

-Alcon Inc. has received FDA approval for a lens designed for implantation during cataract surgery in patients with presbyopia (AcrySof IQ ReSTOR +3.0 D). The lens was introduced outside of the United States in 2008.

“The . . . IOL gives my patients a more comfortable reading distance, improved intermediate vision for tasks such as computer work, and excellent distance vision,” said one study investigator, Kerry Solomon, MD, who is professor of ophthalmology, Medical University of South Carolina, Charleston, and medical director, Storm Eye Institute, Mount Pleasant, SC.

The U.S. clinical trials included a 3-month follow-up exam of near, intermediate, and distance visual acuities. The percentage of patients in whom 20/20 or better vision was achieved at all three distances with the lens was nearly fourfold the rate of patients who received the control lens (AcrySof IQ ReSTOR +4.0 D), according to the company. The clinical studies also demonstrated a high rate of patient satisfaction, with more than 95% of patients stating that they would have the lens implanted again, Alcon relayed.

“Advanced-technology IOLs that correct for presbyopia and astigmatism are the fastest-growing IOL segment of cataract surgery,” said Kevin Buehler, senior vice president, global markets, and chief marketing officer, Alcon. “The addition of this new lens meets a growing desire on the part of cataract patients for spectacle independence after cataract surgery.”

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
© 2025 MJH Life Sciences

All rights reserved.